Boston Scientific Corporation (BSX)

Boston Scientific Corporation's Q·Score is 8.7/10 (Very Bullish), reflecting its current fundamentals, analyst data, and valuation metrics. Clean balance sheet with low leverage (0.4× debt-to-equity). This is an informational data summary only and does not constitute financial advice. Always do your own research before making any investment decision.

The consensus price target for BSX is $85.19, based on ratings from 32 Wall Street analysts. This is 50.8% above the current price of $56.50. Price targets are forward-looking estimates and not guarantees of future performance.

Boston Scientific Corporation (BSX) scores favorably on valuation metrics relative to sector peers and analyst targets. Its forward P/E ratio stands at 15.0×. The consensus analyst price target of $85.19 is 51% above the current price.

Boston Scientific Corporation's next earnings report is expected on approximately July 22, 2026.

Boston Scientific Corporation has a net profit margin of 17.3%, which is solid for most industries. Its gross margin stands at 68.9%, indicating a high-margin business model.

Boston Scientific Corporation is reporting solid revenue growth of 11.6% year-over-year. Earnings are also growing at 100.0%, indicating improving profitability.

Boston Scientific Corporation has a debt-to-equity ratio of 0.42×, reflecting a moderate debt level, which is manageable for most profitable companies. Its current ratio is 1.90×, indicating comfortable short-term liquidity.